nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2015-2-4-79-90nodgo-164Research ArticleКлинические рекомендацииClinical recommendationsФедеральные клинические рекомендации по диагностике и лечению лимфомы Ходжкина (лимфогранулематоз)Federal guidelines for the diagnosis and treatment of Hodgkin's lymphoma (Lymphogranulomatosis)МяковаН. В.MyakovaN. V.

117198, Москва, ул. Саморы Машела, 1

1 Samory Mashela St., Moscow, 117198

nmiakova@mail.ruМасчанА. А.MaschanA. A.

117198, Москва, ул. Саморы Машела, 1

1 Samory Mashela St., Moscow, 117198

РумянцевА. Г.RumyantsevA. G.

117198, Москва, ул. Саморы Машела, 1

1 Samory Mashela St., Moscow, 117198

ФГБУ «ФНКЦ ДГОИ им. Дмитрия Рогачева» Минздрава РоссииРоссияFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of RussiaRussian Federation201503022016247990Copyright © Мякова Н.В., Масчан А.А., Румянцев А.Г., 20162016Мякова Н.В., Масчан А.А., Румянцев А.Г.Myakova N.V., Maschan A.A., Rumyantsev A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/164

Федеральные клинические рекомендации по диагностике и лечению лимфомы Ходжкина (лимфогранулематоз).

Federal guidelines for the diagnosis and treatment of Hodgkin's lymphoma (Lymphogranulomatosis).

ReferencesГематология/онкология детского возраста. Под ред. А.Г. Румянцева и Е.В. Самочатовой. М.: Медпрактика-М, 2004. [Pediatric hematology/oncology. Ed.: Rumyantsev A.G., Samochatova E.V. M.: Medpraktika-M, 2004. (In Russ.)].Гематология/онкология детского возраста. Под ред. А.Г. Румянцева и Е.В. Самочатовой. М.: Медпрактика-М, 2004. [Pediatric hematology/oncology. Ed.: Rumyantsev A.G., Samochatova E.V. M.: Medpraktika-M, 2004. (In Russ.)].Криволапов Ю.А., Леенман Е.Е. Морфологическая диагностика лимфом. СПб.: КОСТА, 2006. [Krivolapov Yu.A., Leenman E.E. Morphological diagnosis of lymphoma. SaintPetersburg: KOSTA, 2006. (In Russ.)].Криволапов Ю.А., Леенман Е.Е. Морфологическая диагностика лимфом. СПб.: КОСТА, 2006. [Krivolapov Yu.A., Leenman E.E. Morphological diagnosis of lymphoma. SaintPetersburg: KOSTA, 2006. (In Russ.)].Самочатова Е.В., Владимирская Е.Б., Жесткова Н.М. и др. Болезнь Ходжкина у детей. М.: Алтус, 1997. [Samochatova E.V., Vladimirskaya E.B., Zhestkova N.M. et al. Hodgkin's disease in children. M.: Altus, 2004. (In Russ.)].Самочатова Е.В., Владимирская Е.Б., Жесткова Н.М. и др. Болезнь Ходжкина у детей. М.: Алтус, 1997. [Samochatova E.V., Vladimirskaya E.B., Zhestkova N.M. et al. Hodgkin's disease in children. M.: Altus, 2004. (In Russ.)].Aleman B.M., Raemaekers J.M., Tirelli U. et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348(24):2396–406.Aleman B.M., Raemaekers J.M., Tirelli U. et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348(24):2396–406.Borchmann P., Haverkamp H., Diehl V. et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011;29(32):4234–42.Borchmann P., Haverkamp H., Diehl V. et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011;29(32):4234–42.Eichenauer D.A., Fuchs M., Pluetschow A. et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocytepredominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118(16):4363–5.Eichenauer D.A., Fuchs M., Pluetschow A. et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocytepredominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118(16):4363–5.Engert A., Eichenauer D.A., Dreyling M.; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v168–71.Engert A., Eichenauer D.A., Dreyling M.; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v168–71.Harris N.L. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol 1999;36(3):220–32.Harris N.L. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol 1999;36(3):220–32.Hoffman R., Benz E.J., Silberstein L.E. et al. Hematology. Basic Principles and Practice, Expert Consult Premium Edition. 6th Edition, 2013, Elsevier Inc. Pp. 1138–1156.Hoffman R., Benz E.J., Silberstein L.E. et al. Hematology. Basic Principles and Practice, Expert Consult Premium Edition. 6th Edition, 2013, Elsevier Inc. Pp. 1138–1156.Koerholz D., Schellong G., Doerffel W. et al. Treatment Recommendations for Children and Adolescents with Hodgkin’s Lymphoma in Russia, 2007.Koerholz D., Schellong G., Doerffel W. et al. Treatment Recommendations for Children and Adolescents with Hodgkin’s Lymphoma in Russia, 2007.Rothe A., Sasse S., Goergen H. et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012;120(7):1470–2.Rothe A., Sasse S., Goergen H. et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012;120(7):1470–2.Schulz H., Rehwald U., Morschhauser F. et al. Rituximab in relapsed lymphocytepredominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111(1):109–11.Schulz H., Rehwald U., Morschhauser F. et al. Rituximab in relapsed lymphocytepredominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111(1):109–11.Senter P.D., Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30(7):631–7.Senter P.D., Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30(7):631–7.Sieniawski M., Reineke T., Nogova L. et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008;111(1):71–6.Sieniawski M., Reineke T., Nogova L. et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008;111(1):71–6.

The authors declare that there are no conflicts of interest present.